The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication.1 Neither product is approved for acute treatment of CDI.
INITIAL EPISODES OF CDI — All...
- Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
- Cariprazine (Vraylar) for Adjunctive Treatment of Depression
- COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
- COVID-19 Update: Metformin to Prevent Long Covid?
- Polatuzumab vedotin (Polivy) for Lymphoma (online only)
- Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
- Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)
Eflapegrastim-xnst (Rolvedon [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.
RECOMBINANT G-CSF …